Life after Merck: What Idenix's Renaud did next

In June, Merck & Co announced it was bolstering its position in the highly competitive hepatitis C arena with the acquisition of Idenix Pharmaceuticals for $3.85bn (scripintelligence.com, 9 June 2014). The transaction closed in August.